Wilkowske C J, Hermans P E
Mayo Clin Proc. 1983 Jan;58(1):6-13.
The initial treatment of suspected life-threatening bacterial infection should be sufficiently broad to cover the likely causative agents. Definitive therapy depends on microbial isolation, identification, and, when indicated, in vitro susceptibility tests. Parenteral therapy should be used, at least initially, and optimal doses are necessary. The dose is particularly important when aminoglycosides are administered; a concern for potential side effects with use of these agents had engendered a tendency to administer inadequate doses. The problems leading to recurrence or persistence of fever during antimicrobial therapy include failure to diagnose and drain abscesses, superinfection, drug fever, and clinical or microbiologic errors. Combinations of antibiotics are indicated in severe infections due to Pseudomonas aeruginosa, enterococcal group D streptococci, and Cryptococcus neoformans. Laboratory assistance for the selection of antimicrobial therapy can be valuable but is not always necessary because certain microorganisms--for example, Streptococcus pneumoniae and S. pyogenes--have stable, predictable susceptibilities. Cautious conservatism is advocated with regard to the use of new antimicrobial agents.
对于疑似危及生命的细菌感染,初始治疗应足够广泛,以覆盖可能的病原体。确切的治疗取决于微生物的分离、鉴定,以及必要时的体外药敏试验。至少在初始阶段应采用肠外治疗,且需要使用最佳剂量。使用氨基糖苷类药物时,剂量尤为重要;对这些药物潜在副作用的担忧导致了用药剂量不足的倾向。抗菌治疗期间导致发热复发或持续的问题包括未能诊断和引流脓肿、二重感染、药物热以及临床或微生物学错误。对于由铜绿假单胞菌、D组肠球菌和新型隐球菌引起的严重感染,需联合使用抗生素。实验室协助选择抗菌治疗可能很有价值,但并非总是必要的,因为某些微生物——例如肺炎链球菌和化脓性链球菌——具有稳定、可预测的药敏性。在使用新型抗菌药物方面,提倡谨慎保守。